Capital Counsel LLC NY Buys 1,058 Shares of Gilead Sciences, Inc. $GILD

Capital Counsel LLC NY increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,210 shares of the biopharmaceutical company’s stock after purchasing an additional 1,058 shares during the period. Gilead Sciences makes up 0.3% of Capital Counsel LLC NY’s holdings, making the stock its 17th biggest holding. Capital Counsel LLC NY’s holdings in Gilead Sciences were worth $7,673,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after buying an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after acquiring an additional 727,515 shares in the last quarter. Norges Bank bought a new position in Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Price T Rowe Associates Inc. MD raised its position in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.3%

Shares of NASDAQ GILD opened at $125.85 on Monday. The company has a 50 day simple moving average of $119.87 and a 200 day simple moving average of $114.70. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The firm has a market cap of $156.13 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Buying and Selling

In other news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the transaction, the executive vice president directly owned 43,676 shares in the company, valued at $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider directly owned 107,193 shares in the company, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 115,146 shares of company stock valued at $14,012,141 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GILD. Royal Bank Of Canada lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research note on Friday, October 31st. BMO Capital Markets set a $135.00 target price on Gilead Sciences in a research note on Tuesday, November 25th. TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.